Drugs / emilimogene sigulactibac
emilimogene sigulactibac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05608187 | Sep 2022 → Dec 2024 | ulcer of lower limbs | Ilya Pharma | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | emilimogene sigulactibac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05608187 ↗ |
| Known as | Emilimogen sigulactibac | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095118 ↗ |
| Known as | ILP-100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095118 ↗ |
| Known as | Ipl100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095118 ↗ |
| Route | Topical | “topically administered” NCT05608187 ↗ |